Background
==========

Mounting evidence linking environmental exposures in early life to later risk of cardiovascular disease has led to intense interest in the process of vasculature development *in utero*\[[@B1]-[@B3]\]. Primarily, arteries and veins are defined by physiologic factors such as the direction and pressure of blood flow and by functional and anatomical differences such as the arrangement of smooth muscle cells around the vessels. In general, arteries carry oxygenated blood, and have tighter endothelial junctions, whilst veins carry deoxygenated blood and have looser endothelial junctions \[[@B4]\]. The feto-placental vascular system differs from that of most other human organs, because the arteries carry the deoxygenated blood coming from the fetus whilst the veins carry the oxygen enriched blood.

Not surprisingly, given their different physiologic functions, the identity of arterial and venous endothelial cells is established before the onset of circulation \[[@B5]-[@B7]\] in association with distinct gene expression signatures that define endothelial cell identity \[[@B8]-[@B10]\]. This includes endothelial nitric oxide synthase (eNOS) encoded by *NOS3*, von Willebrand factor (vWF), vascular endothelial cadherin (VE-cadherin, *CDH5*), intracellular adhesion molecular-2 (*ICAM-2*), endothelial growth factor receptor tyrosine kinases VEGF-R1 (*Flt-1*) and VEGF-R2 (*Flk-1, KDR*), angiopoietin receptors Tie-1 and Tie2 (*TEK*) and NOTCH4 \[Reviewed in \[[@B11],[@B12]\]\]. In addition, a number of transcription factors have been shown to be preferentially expressed in endothelial progenitor cells and mature endothelial cells and have been argued to orchestrate the expression of such genes \[[@B11]\]. Despite this, the associated epigenetic regulators determining this specific gene expression profile are largely unclear.

Numerous lines of evidence suggest that the endothelial compartment represents a potential target tissue for transmission of environmentally mediated risk of complex disease, potentially via a process of epigenetic disruption in early development \[[@B2],[@B13]\]. Epigenetic mechanisms, including DNA methylation, are now widely accepted to underpin developmentally regulated changes in cell morphology and function \[[@B14]\], however little is known about the role of such modifications, and their relative plasticity, during endothelial cell development. It is clear that one of the key regulators of vascular function, endothelial nitric oxide synthase (eNOS) is under epigenetic control by several mechanisms, including DNA methylation \[[@B15]\]. Indeed the chromatin structure of the eNOS promoter is transcriptionally permissive only in cells of the endothelial compartment, such as those isolated from human umbilical vein, mouse aortic, and pooled human dermal microvascular endothelial cells \[[@B15],[@B16]\]. Altered chromatin has also been reported for other endothelial-specific genes including *vWF*\[[@B17]\], *NOTCH4*\[[@B18]\]. Furthermore, studies have shown changes in epigenetic marks induced by oxidative stress (i.e. hypoxia) in *VEGF*\[[@B19]\] and *NOS3*\[[@B20]\], supporting the potential epigenetic roles in tissue-specific regulation of those genes. Recent genome-scale comparison of DNA methylation in dermal derived lymphatic and blood-derived endothelial cells has highlighted the role of differential methylation in the specification of endothelial function \[[@B21]\], but beyond these limited data, little is known about the relationship between epigenetic modifications and gene expression underpinning endothelial phenotype or developmental stage at the genome-wide level. As a first step towards addressing these questions, we have examined the relationship between genome-scale DNA methylation and gene expression in purified human placental arterial and venous endothelial cells (HPAEC and HPVEC).

Results and Discussion
======================

Placenta-derived venous and arterial endothelial cells play especially important functional roles (e.g. nutrition, cholesterol delivery) as part of the fetal-maternal supply line \[[@B22],[@B23]\]. Furthermore, several physiological differences exist between these two cell types \[[@B24]\] and they differ in their degree of maturity. Whereas placental arterial endothelial cells have a mature arterial phenotype (fully differentiated), venous derived cells show a juvenile (less differentiated) phenotype, potentially representing a pool of endothelial progenitor cells \[[@B9]\].

We compared DNA methylation in 9 purified cell populations each of Human Placental Arterial Endothelial Cells (HPAEC) and venous equivalents (HPVEC). After removing probes that did not pass a quality control cutoff (i.e. probes with \>0.05 p-value detection) and probes on sex chromosomes, a total of 351,952 probes remained that were common to all datasets for inclusion in subsequent analyses. β-values (DNA methylation values between 0 and 1, approximating 0-100% methylation) were calculated for each probe in HPAEC and HPVEC samples.

General hypomethylation in placental venous relative to arterial endothelial cells
----------------------------------------------------------------------------------

As a first comparison of methylation within the two cell types, we calculated an average β-value across the entire dataset as a proxy for global methylation levels in venous and arterial cell samples as previously described \[[@B25]\]. Interestingly, we found clear evidence for a general hypomethylation in HPVEC (average β = 0.434) relative to HPAEC (average β = 0.479), with the latter comparable to peripheral blood average methylation, whereas HPVEC levels were more similar to that of buccal cells taken at birth. Both HPAEC and HPVEC were generally more methylated on average than placental tissue (Figure [1](#F1){ref-type="fig"}).

![**Comparison of average DNA methylation levels across \>300,000 CpG sites in HPAEC (n=9) and HPVEC (n=9).** The average β-value across the entire dataset was generated as a proxy for global methylation levels as previously described \[[@B25]\]. Hypomethylation of HPVEC was observed (average β = 0.434) relative to HPAEC (average β = 0.479). Peripheral blood (n=40), Buccal (n=59) and Placenta (n=19) were included for comparative purposes.](1471-2164-14-475-1){#F1}

Widespread epigenetic differences in placental arterial and venous endothelial cell compartments
------------------------------------------------------------------------------------------------

Importantly, where tested, HM450 DNA methylation levels showed strong correlations with those derived using locus-specific SEQUENOM MassARRAY EpiTYPER platform (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S3), validating the HM450 platform, in accordance with other recent studies \[[@B26]-[@B29]\]. Unsupervised hierarchical clustering of variable probes in this dataset (SD/mean \> 0.4; 151453 probes) clearly discriminated arterial from venous samples (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1) highlighting the genome-wide DNA methylation differences between these endothelial compartments. HPAEC were more variable as a group than HPVEC in terms of DNA methylation profile. This discriminatory capacity was maintained following unsupervised clustering of the 1000 most highly variable probes (Figure [2](#F2){ref-type="fig"}). Further, a similar comparison with recently reported methylation datasets generated from cultured adult dermal blood and lymphatic endothelial cell populations \[[@B21]\] with our dataset, along with unpublished Human Umbilical Vein Endothelial cell (HUVEC) data, highlights the distinct DNA methylation profile of endothelial source from different vascular compartments. HPVEC show the most unique methylation profile, clustering separately from lymphatic and blood derived endothelial cells, HUVECs and HPAEC cells (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S2).

![**Unsupervised hierarchical clustering (dendrogram) and heatmap of 1000 most highly variable probes in HPAEC and HPVEC samples.** Despite evidence of variability in DNA methylation profile within each cell type, HPAEC and HPVEC samples are clearly discriminated according to methylation profile.](1471-2164-14-475-2){#F2}

To identify sets of differentially methylated probes (DMPs) between HPAEC and HPVEC, average β-values were calculated for each probe in HPAEC and HPVEC groups. Linear regression analysis revealed a large set of significantly differentially methylated probes (95,266 in total; Benjamini-Hochberg adjusted p-value ≤ 0.05). A total of 15,115 probes, associated with 5,142 genes, showed elevated methylation in HPVEC relative to HPAEC (average β-value difference ≥0.10; Additional file [2](#S2){ref-type="supplementary-material"}: Table S2) whereas 53,725 probes associated with 12,659 genes showed the reciprocal pattern (Additional file [3](#S3){ref-type="supplementary-material"}: Table S3). These data highlight the coordinated nature of methylation change, with blocks of probes (differentially methylated regions -- DMRs), showing a common shift in the direction and magnitude of methylation change between cell types.

In order to examine the potential for altered DNA methyltransferase activity to explain the observed global DNA methylation differences described above, we extracted methylation and gene expression data for found evidence for differential methylation of both the DNMT1 and DNMT3A (but not DNMT3B) genes, with elevated average methylation in both promoter regions in HPVEC relative to HPAEC (Additional file [4](#S4){ref-type="supplementary-material"}: Table S1). Further, this was associated with a reciprocal pattern of gene expression specifically for DNMT3A consistent with methylation induced down regulation of DNMT activity in the placental venous compartment (Additional file [4](#S4){ref-type="supplementary-material"}: Table S1).

Of particular interest to endothelial cell biology, many DMP/DMRs were identified in genes previously implicated in endothelial functioning, including nitric oxide synthase 2 (iNOS) \[[@B12],[@B30]\] and *NOS3* (encoding eNOS) \[[@B15],[@B31]\], von Willebrand Factor (*VWF*) \[[@B11]\], *NOTCH4*\[[@B18]\], *VEGFA, VEGFC*\[[@B32]\]*,SELE*\[[@B33]\], *FLT*\[[@B34]\]*,* and *KDR*\[[@B35]\] genes, although the number of DMPs and direction of methylation difference between cell types was variable (Additional file [2](#S2){ref-type="supplementary-material"}: Tables S2 and Additional file [3](#S3){ref-type="supplementary-material"}: Table S3).

Interestingly, many genes showed a reciprocal effect on methylation profile according to genomic location relative to the transcription start site. For example, *NOS3*, showed two regions of highly significant differential methylation. The first, located in the major promoter previously described to drive endothelial expression, encompassed 4 probes with higher mean methylation in HPVEC relative to HPAEC cells, while a reciprocal mean methylation pattern was observed for 5 probes in a downstream exon-associated region in a previously described, placenta-specific variant of this gene (Figure [3](#F3){ref-type="fig"}). Locus-specific analysis of methylation confirmed highly differential methylation across each of these regions (Figure [3](#F3){ref-type="fig"}D), however the regulatory function (if any) of this second region remains to be determined. Such complex patterns of methylation within individual genes have recently emerged as a common feature in gene regulation in humans \[[@B36]-[@B38]\].

![***NOS3*gene methylation levels vary according to genomic location in HPAEC and HPVEC cells. A**. UCSC Genome Browser View of *NOS3* showing chromosomal coordinates (Chr7 - chromosome 7), location of HM450 array probes, CpG sites (black vertical dashes), alternative splice variants including differential exons (blue bar) and introns (arrowed lines), CpG islands (green bar). **B**. Magnified view of regions of differential methylation of the *NOS3* gene between HPAEC and HPVEC. **C**. Graphical summary of mean *NOS3* methylation level (y-axis) in HPAEC (open triangles; n=9) relative to HPVEC (closed squares; n=9) for HM450 probes 1--14 in A. (x-axis) highlights a region of methylation of the major *NOS3* promoter (i) and reciprocal hypomethylation of a downstream CpG island (iii) in HPVEC relative to HPAEC cells . Error bars denote 95% confidence interval and asterisks denote level of significance of array data according to adjusted p-value from linear regression analysis. **D**. DNA Methylation patterns detected by Sequenom EpiTYPER around the two regions corresponding to the HM450 probes. This cross-platform analysis further confirms the methylation of the major *NOS3* promoter in HPVEC (i) and the reciprocal hypomethylation of the downstream CpG island (ii) Error bars -- 95% confidence interval.](1471-2164-14-475-3){#F3}

*NOS3* is constitutively expressed in the vascular endothelium and plays a critical role in cardiovascular physiology as evidenced by systemic and pulmonary hypertension, abnormal vasculature, defective angiogenesis, poor healing in response to injury and impaired mobilization of stem cells, in eNOS-null mice \[reviewed in \[[@B39]\]\]. Disruption of methylation in either of these regions early in development could be a modifiable risk factor for disease in later life.

Complex interplay between endothelial DNA methylation and gene expression
-------------------------------------------------------------------------

Extensive epigenetic studies have highlighted the complex relationship between DNA methylation and gene expression levels. In addition to the well documented role of elevated methylation at promoter-associated CpG islands in down-regulation of gene expression, it is also apparent that some methylation marks at these (and other) sites may be independent of gene expression status, or even predict active expression, as observed in several DMRs of imprinted genes or in the case of gene-body methylation \[[@B36]-[@B38]\]. Thus, in order to examine the relationship between DNA methylation and gene expression, we integrated the methylation and gene expression data sets. For each HM450 probe, differences in β-values between the two groups (Δβ) were calculated and these were compared with corresponding gene expression differences (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S5). By setting cutoffs in average methylation difference higher than 10% (Δβ \> 0.1) and log2 fold change in gene expression of \~1.4 (0.5 logFC), we identified a subset of genes that showed a reciprocal relationship between methylation and expression level in HPVEC and HPAEC (Figure [4](#F4){ref-type="fig"}; Additional file [1](#S1){ref-type="supplementary-material"}: red dots in Figure S5), consistent with a role of increasing methylation in down-regulation of gene expression. This includes 866 HM450 probes showing lower methylation in association with elevated expression of 306 genes in arterial cells (Additional file [5](#S5){ref-type="supplementary-material"}: Table S6), and 2388 probes covering 513 genes showing the same relationship in venous cells (Additional file [5](#S5){ref-type="supplementary-material"}: Table S7).

![**Scatterplot of DNA methylation (x-axis) and gene expression (y-axis) differences between HPVEC and HPAEC for genes showing reciprocal methylation/gene expression change.** Gates were set at the limits of technical noise (methylation +/− 10%, gene expression +/− 0.5 fold change). Each set of HM450 probe datapoints (x-axis) with a common set of gene expression values (y-axis) represents a gene likely to be under epigenetic regulation by DNA methylation with decreased methylation associated with elevated gene expression in HPAEC relative to HPVEC **(A)** and vice versa **(B)**. Genes highlighted in red included NOS3 and vWF. Note that in many instances, genes contain multiple HM450 probes for each gene expression measure.](1471-2164-14-475-4){#F4}

In order to test for any pattern regarding genomic location and likelihood of regulating gene expression, we examined the proportion of each probe type showing coordinate changes in differential methylation and gene expression, according to annotation (promoter-associated, location within 1500 bp of transcription start site, gene-body, and enhancer-associated). This revealed that the majority of probes were located in enhancer or upstream regulatory (TSS1500, promoter) regions (Table [1](#T1){ref-type="table"}, Additional file [1](#S1){ref-type="supplementary-material"}: Figure S6).

###### 

Number of differentially methylated probes sorted by genomic region

                                                                                                       **All probes**              **Probes located within 1500 bp upstream, 5\'UTR and 1st Exon ("non‒gene body" probes)**   **5\'UTR and 1st Exon ("non‒gene body" probes) Transcription Start Site (Excludes 5'UTR/1st Exon)**                                                                                                                                  
  ----------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------- ------------- ------------------------------------- -------------------------------------
   Quadrant number Additional file [1](#S1){ref-type="supplementary-material"}: Figure S4)               Probe Count                                         Proportion to total probes in group                                                                          Probe Count                                               Proportion to total probes in group   Proportion to all analysable probes   Probe Count   Proportion to total probes in group   Proportion to all analysable probes
                                                                                                           351952                                                          100.00%                                                                                          184099                                                                100.00%                               52.31%                    130656                    100.00%                               37.12%
                                           **Q1**                                                            866                                                            0.25%                                                                                             462                                                                  0.35%                                 0.13%                      292                      0.22%                                 0.08%
                                           **Q2**                                                           3441                                                            0.98%                                                                                             955                                                                  0.73%                                 0.27%                      619                      0.47%                                 0.18%
                                           **Q3**                                                           2388                                                            0.68%                                                                                            1011                                                                  0.77%                                 0.29%                      627                      0.48%                                 0.18%
                                           **Q4**                                                            711                                                            0.20%                                                                                             301                                                                  0.23%                                 0.09%                      179                      0.14%                                 0.05%
                                                                                               **Probes on Enhancer Regions**                                   **Promoter Associated Probes**                                                            **Gene Body Only (not 5'UTR or 1st Exon)**                                                                                                                                                               
                                         Probe Count                                         Proportion to total probes in group                             Proportion to all analysable probes                                                                          Probe Count                                               Proportion to total probes in group   Proportion to all analysable probes   Probe Count   Proportion to total probes in group   Proportion to all analysable probes
                                            59317                                                          100.00%                                                          16.85%                                                                                           91601                                                                100.00%                               26.03%                    146423                    100.00%                               41.60%
                                             275                                                            0.46%                                                           0.08%                                                                                             97                                                                   0.11%                                 0.03%                      359                      0.25%                                 0.10%
                                            1239                                                            2.09%                                                           0.35%                                                                                             145                                                                  0.16%                                 0.04%                     2220                      1.52%                                 0.63%
                                             960                                                            1.62%                                                           0.27%                                                                                             214                                                                  0.23%                                 0.06%                     1221                      0.83%                                 0.63%
                                             286                                                            0.48%                                                           0.08%                                                                                             65                                                                   0.07%                                 0.02%                      379                      0.26%                                 0.11%

Q1, probes showing less methylation (\<-10%) and higher expression (\>0.5 LogFC); Q2, probes showing higher methylation (\>10%) and expression; Q3, probes showing higher methylation and less expression (\<-0.5 LogFC); Q4, probes showing less methylation and expression in HPAEC relative to HPVEC, Genomic regions may overlap between one or more categories (e.g. a probe can be located in 1500 bp from upstream and also be associated with Enhancer and/or Promoter).

Interestingly, endothelial genes likely to be directly regulated by DNA methylation in our dataset included *NOS3, vWF, APOLD1, ANGPTL2* genes. Many endothelial genes show both differential methylation at upstream regulatory regions and gene expression differences, but not always in the anticipated reciprocal direction (Table [2](#T2){ref-type="table"}A, Additional file [5](#S5){ref-type="supplementary-material"}: Table S8; Additional file [1](#S1){ref-type="supplementary-material"}: Figure S5).

###### 

DNA Methylation of probes located near transcription start sites of selected genes associated in endothelial function and corresponding gene expression levels

   **Selected genes showing changes in both promoter methylation and gene expression**                                                                                                                                        
  ------------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------ ------------------------------- ------------------------------------------------------------------
                                         *NOS3*                                                           Nitrix Oxide Synthase                                      -1.233                                0.314                                          6/28 (21%)
                                          *vWF*                                                           von Wildebrand Factor                                      -2.523                                0.124                                          4/38 (11%)
                                          *MGP*                                                             Matrix Gla protein                                       -3.202                                0.225                                          1/3 (33%)
                                         *GJA5*                                                                 Connexin40                                           -3.434                                0.122                                          7/15 (47%)
                                        *APOLD1†*                                         apolipoprotein L domain containing 1 \[Homo sapiens\]                      -0.061                                0.684                                          7/32 (22%)
                                        *HIF3A†*                                                Hypoxia Inducible Factor 3, alpha subunit                            -0.599                               -0.161                                          8/23 (35%)
                                        *EphB1†*                                                        Ephrine type-B receptor 1                                    1.050                                 0.284                                          2/36 (6%)
                                        *ANGPTL†*                                                          Angiopoietin-like 2                                       0.768                                -0.178                                          2/6 (33%)
                                         *SELE†*                                                                E-Selectin                                           0.934                                 0.165                                          2/3 (67%)
                                    *FLT1 (VEGFR1) †*                                         Vascular Endothelial Growth Factor Receptor 1                          0.930                                 0.333                                          3/28 (11%)
                                        *COL6A3*                                                        Collagen, type VI, alpha 3                                   4.117                                -0.128                                          9/53 (17%)
                                        *HSD11B1*                                                Hydroxysteroid (11-beta) Dehydrogenase 1                            1.092                                -0.177                                          8/9 (89%)
                                         *VEGFC*                                                   Vascular Endothelial Growth Factor C                              0.662                                -0.101                                          5/13 (38%)
                                          *HGF*                                          Hepatocyte Growth Factor (hepapoietin A; scatter factor)                    3.973                                -0.092                                          7/10 (70%)
                                        *ANGPT1*                                                              Angiopoietin 1                                         1.172                                -0.210                                          2/16 (13%)
         **Genes showing expression changes but no changes in DNA methylation**                                                                                                                                               
                                     **Gene symbol**                                                         **Description**                        **Gene expression LogFC (HPAEC ‒ HPVEC**   **Average β of HPAEC ‒HPVEC**   **Probes located in promoter region / total number of probes\***
                                         *ARG2*                                                                 Arginine 2                                           0.445                                \<0.001                                        11/15 (73%)
                                         *DLL1*                                                       Delta like protein 1 precursor                                 0.077                                 0.005                                         12/38 (32%)
                                         *JAG1*                                                             Jagged 1 precursor                                       0.605                                \<0.001                                        10/24 (42%)
                                         *JAG2*                                                             Jagged 2 precursor                                       0.369                                \<0.001                                         8/47 (17%)
                                     *KDR (VEGFR2)*                                                   Kinase Insert Domain Receptor                                  1.552                                 0.003                                          9/16 (56%)
                                         *HEY2*                                             hairy/enhancer‒of‒split related with YRPW motif 2                        1.506                                \<0.001                                        11/21 (52%)
                                         *NOTCH*                                          neurogenic locus notch homolog protein 4 preproprotein                     0.429                                 0.024                                          3/160 (2%)
                                         *EphB2*                                          neurogenic locus notch homolog protein 4 preproprotein                     0.262                                 0.007                                          5/46 (11%)
                                         *NRP1*                                                                Neuropilin 1                                          0.529                                 0.002                                          6/29 (21%)
                                         *EphB4*                                                        Ephrine type‒B receptor 4                                    0.732                                \<0.001                                         7/29 (24%)
                                         *EphB4*                                                     Intercelluar adhesion molecule‒2                                0.808                                 0.029                                         11/15 (73%)

\* denotes number of probes located near promoter regions of each gene where highly differential DNA methylation patterns were detected between two cell types out of total numbers of probes associated with each gene. † denotes probes where strong DNA methylation differences and gene expression patterns were detected but not inverse relationship. It may indicate there exists other regulatory regions or gene expression is regulated by epigenetic mechanism other than DNA methylation.

The *FLT1* and *KDR* genes code for two different subtypes of VEGF receptors. These genes have previously been shown to be expressed in most endothelial cells including aortic, vein, microvessel and in many tumors, albeit variably across tumors and individuals \[[@B40]-[@B42]\]. FLT1 and KDR are postulated to play a significant role in angiogenesis and/or tumor progression by influencing the activity of *VEGF*\[[@B43],[@B44]\]. These genes are shown to be hypermethylated in some cancer cell lines (e.g. colon, stomach) \[[@B41]\]. In our study, *FLT1* showed differential promoter methylation and gene expression in HPAEC and HPVEC, however expression and methylation were positively correlated rather than anti-correlated (Table [2](#T2){ref-type="table"}). In contrast, the *KDR* gene was differentially expressed between two cell types but this was independent of any DNA methylation differences in the vicinity of the transcription start site. These findings are interesting given that previous studies have shown down regulation of each of these genes in association with promoter methylation in various cell lines, while cell lines expressing KDR (including HUVECs) appear universally unmethylated \[[@B41],[@B45]\].

The *TLR2* gene has previously been shown to be expressed in endothelial cells in a cell-type specific manner \[[@B46]\]. We found no significant gene expression difference in *TLR2* in HPVEC relative to HPAEC (average log FC \< 0.073) despite significant differences in promoter methylation levels, with HPVEC having higher regional methylation (average Δβ = 0.213), spanning seven HM450 probes, located proximal to the transcription start site. The activity of this gene in HUVECs has previously been shown to be regulated by inflammation in the absence of altered DNA methylation in HUVECs \[[@B47]\].

In combination these data highlight the differential and complex role of epigenetics in the regulation of gene expression in endothelial cells of different origin, with several genes likely to be regulated by alternative epigenetic mechanisms (such as histone modification and/or non-coding RNAs) in a cell context-dependent manner. Differential utilization of genomic regulatory elements or expression of upstream transcription factors may also contribute to the observed pattern of expression.

Epigenetic regulation of miR expression in endothelial cells?
-------------------------------------------------------------

Multiple examples of miRNA gene differential methylation were apparent in HPAEC and HPVEC cells (Additional file [5](#S5){ref-type="supplementary-material"}: Table S9), including miRs previously implicated in regulation of endothelial function and/or angiogenesis such as miR-126 and miR-130A \[[@B48]\]. Interestingly miR-200 family members (miR200-A, --B and --C), involved in regulation of VEGF signaling in endothelial cells \[[@B49]\], were found to be more highly methylated in HPAEC than HPVEC. Furthermore, miR-10A-associated probes, previously linked with arthero-function, were specifically hypermethylated in HPAEC relative to HPVEC \[[@B50]\]. In contrast, the gene encoding miR-125B, a translational suppressor of VE-cadherin \[[@B51]\], were hypermethylated in HPVEC, relative to HPAEC. Despite the clear evidence of differential methylation, an examination of miR expression profiles failed to reveal a corresponding difference in gene expression between the two cell types (data not shown). Thus, the biological significance of the methylation differences remains.

Ontology of genes associated with DMRs
--------------------------------------

In order to more fully understand any biological/cellular functions subject to coordinated regulation in endothelial cells, we performed gene ontology and Ingenuity Pathway Analyses (<http://www.ingenuity.com>) on differentially methylated genes. Prior to the analysis, the list of DMPs was selectively culled to focus on those probes predicted to play a role in gene regulation according to genomic location (associated with gene promoters, enhancers, 5' UTR, or TSS associated regions as specified by the HM450 manifest annotation file HM450_V1.2). Ingenuity Pathway Analysis revealed an enrichment of genes involved in biological functions such as "Tissue Development", "Cardiovascular System Development and Function", and "Tissue Morphology" as differentially methylated in HPAEC and HPVEC (Additional file [5](#S5){ref-type="supplementary-material"}: Table S4). Many of these genes warrant further investigation in the development of arterial or venous endothelial cell phenotype. Gene Ontology Analysis performed by DAVID (<http://david.abcc.ncifcrf.gov/>, \[[@B52]\]) highlighted related biological processes associated with the "Extracellular matrix", previously shown to be critical for proper vascular development \[[@B53]\], and "Plasma membrane" and "Vasculature Development" (Additional file [5](#S5){ref-type="supplementary-material"}: Table S5). Importantly, coordinated regulation of genes involved in specific cellular pathways such as "cardiovascular pathway genes" was apparent (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S4).

Conclusion
==========

Placenta-derived arterial and venous endothelial cells differ in both their functional characteristics \[[@B24]\] and differentiation state \[[@B9]\]. Whereas arterial cells are mature and fully differentiated, their venous counterparts have been regarded as immature, representing a juvenile phenotype with a high degree of plasticity. We speculate that differential phenotype of these cells is largely driven by distinct gene expression changes, many of which are mediated by promoter methylation differences in key genes identified here. At present it is not possible to distinguish which epigenetic changes are associated with the degree of maturity of the cells, and which drive more general distinct differences in venous vs arterial characteristics. This will require further investigation.

The two cell types examined show a distinct difference in global DNA methylation level, with the HPVEC hypomethylated relative to HPAEC, and other endothelial cells from a variety of tissues. The low average methylation seen in the venous compartment is reminiscent of the hypomethylation seen in placental tissue and may be one of the underlying mechanisms by which environmental cues modulate their phenotype to adapt to the microenvironment. Indeed, the HPVECs are more sensitive to changes in their local environment *in vitro* relative to the HPAEC counterparts \[[@B53]\].

To the best of our knowledge this is the first study comparing global gene expression and DNA methylation of primary arterial and venous endothelial cells isolated from the same organ. In general our data have revealed a highly coordinated series of DNA methylation events, many of which are directly implicated in regulating underlying gene expression levels, while the functional significance of others is less apparent. Included in our dataset are numerous genes previously not studied in relation to endothelial function, that warrant such an investigation in future studies. The combination of DNA methylation and gene expression profiling of early life endothelial cells represents a powerful approach to identify candidate loci potentially subject to environmentally mediated epigenetic disruption, in association with modified risk of later complex diseases involving cardiovascular dysfunction.

Methods
=======

HPAEC and HPVEC: isolation and culturing
----------------------------------------

Primary HPAEC and HPVEC were isolated from arteries and veins, respectively dissected from placentas after uncomplicated vaginal delivery as described previously \[[@B9]\]. Each of the 9 venous and arterial endothelial cell pairs used here was isolated from the same vascular loop of 9 full term human placentas. Cells were cultured on 1% (v/v) gelatin-coated plates using Endothelial Basal Medium (EBM, Cambrex, Clonetics™, Walkersville, MD) supplemented with the EGM™-MV BulletKit (Clonetics™). They were characterized by internalization of acetylated low-density-lipoprotein and immunohistochemical staining for the endothelial cell marker von Willebrand factor and negative staining for fibroblast-specific antigen and smooth muscle actin \[[@B9]\]. Only HPAEC and HPVEC pairs, i.e. isolated from the same placentas, were used in order to minimize variance.

Nucleic acid purification and QC
--------------------------------

Total RNA from HPAEC and HPVEC was isolated with RNeasy mini kit (QIAGEN, Dusseldorf, Germany) and scrutinized for quality on the BioAnalyzer BA2100 (Agilent, Santa Clara, CA, USA) with the RNA 6000 Nano Chip Kit (Agilent, Cat No 5067--1511). The RIN (RNA Integrity Number) of the samples ranged between 8.7 and 10. Genomic DNA from HPAEC and HPVEC was isolated using phenol/chloroform density gradient centrifugation method as described previously \[[@B54]\].

Genome-scale DNA methylation analysis: data acquisition and processing
----------------------------------------------------------------------

A total of 1 μg of DNA isolated from 9 HPAEC and 9 HPVEC cell populations was bisulphite converted using the MethylEasy™ bisulphite modification kit (Human Genetic Signatures, Sydney, Australia), according to the manufacturer's instructions. Unpublished HUVEC data used for unsupervised hierarchical clustering were obtained from purified cells isolated as previously described \[[@B55]\]. Unpublished HM450 data from buccal cells, peripheral blood and placental tissue, used for a comparative analysis of average β values across over 300,000 genomic loci, was kindly provided by Drs Jeff Craig and Boris Novakovic, Murdoch Childrens Research Institute. Conversion efficiency was assessed by bisulphite-specific PCR. Hybridization of bisulphite-treated samples to Illumina Infinium Human Methylation450 (HM450) Beadchips was performed at the Australian Genome Research Facility (AGRF). Raw data files were exported from Genome Studio (Illumina, San Diego, CA) into the R statistical environment (<http://cran.r-project.org/index.html>). Infinium HM450 data was normalised using the SWAN method from the *minfi* package available from Bioconductor \[[@B56],[@B57]\]. This has been specifically designed for such platform where a bias from the two types of probes is apparent. M-values were calculated after removing probes on the sex chromosomes to eliminate any potential gender bias and any poor performing probes, defined as those with a detection p-value cut-off \> 0.05 in any sample. β-values were derived from intensities as defined by the ratio of methylated to unmethylated probes given by β =M / (U+M) and were used as a measure of effect size.

Gene expression array analysis: data acquisition and processing
---------------------------------------------------------------

Total RNA was labeled using Affymetrix GeneChip® Whole Transcript (WT) Sense Target Labeling Kit (Affymetrix, Santa Clara, CA, USA; Cat No. 900652) and then prepared for hybridization. For expression analysis RNA was hybridized against GeneChip® Human 1.0 ST arrays (Affymetrix, Cat No. 901087) according to the manufacturer's instructions. Labeling and hybridization controls were evaluated with Expression Console EC 1.1. Hybridizations and analysis were carried out at the Division Core Facility for Molecular Biology at the Centre of Medical Research at the Medical University of Graz. Microarray data were analysed with Partek Genomic Suite v6.4 software (Partek Inc, St Louis, MO, USA). The import process of the CEL files contained RMA normalization (robust multi-chip average) including background correction, quantile normalization across all arrays and median polished summarization based on log transformed expression values. Significant different genes were extracted with FDR5% / p\<0.005 / p\<0.05 using ANOVA. Annotations were obtained from NetAffx (Affymetrix).

Statistical analysis and bioinformatics
---------------------------------------

The Benjamini--Hotchberg method was used for controlling the false discovery rate and correct for multiple testing when comparing HPAEC and HPVEC methylation \[[@B58]\]. The HM450 data (M-value) underwent unsupervised hierarchical clustering analysis using the *lumi* package \[[@B59]\]. Linear regression analysis was performed using the *limma* package \[[@B60]\]. For combined gene expression and DNA methylation analysis, Δβ values (average β-values of HPVEC subtracted from average values of HPAEC) were plotted against the average Log~2~ fold gene expression change of HM450 gene-associated probes. To determine the association between genomic location and differential methylation status, HM450 probes were exclusively assigned to one of the following groups based on the HM450 manifest annotation file version 1.2: promoter associated; enhancer associated; within 1500 bp upstream of a transcription start site (TSS); within 1500 bp upstream of a gene, 5'UTR and first exon; and probes located in gene body and 3'UTR only. Gene Ontology and pathway analysis was performed using the DAVID bioinformatics tool (david.abcc.ncifcrf.gov/) \[[@B61]\] and Ingenuity Pathway Analysis (<http://www.ingenuity.com>) under the default settings.

Gene specific DNA methylation
-----------------------------

*NOS3* locus-specific methylation was performed using the Sequenom EpiTYPER MassARRAY platform (Sequenom, San Diego, USA) as previously described \[[@B62],[@B63]\]. Amplicons were designed using EpiDesigner software (<http://www.epidesigner.com/>) and amplification conditions were as follows: 95°C for 10 min; 95°C for 10 s, 56°C for 30 s, and 72°C for 1 min 30 s for 40 cycles; 72°C for 7 min. Primer and target sequences, along with amplification cleavage product patterns and analyzable CpG units are provided in Additional file [1](#S1){ref-type="supplementary-material"}: Figure S7.
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Human placental tissue was obtained at term of gestation from uncomplicated pregnancies. All women were lean (BMI 20--24.9), non-smokers and with blood pressure in the normal range. All underwent an oral Glucose Tolerance Test between weeks 24 and 28 and their blood pressure was measured at each visit. Values were in the normal range (ie. did not exceed threshold levels to classify the women as being diabetic/gestational diabetic or having pregnancy-induced hypertension/pre-eclampsia). Informed consent was obtained and ethical approval was granted by the ethics committee of the Medical University of Graz. This study meets the principles of the Declaration of Helsinki.
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###### Additional file 1: Figure S1

Unsupervised hierarchical clustering of probes showing variable DNA methylation levels (coefficient of variation \>0.4) in HPAEC and HPVEC samples. **Figure S2.** Unsupervised hierarchical clustering of probes showing variable DNA methylation levels (coefficient of variation \>0.4) in endothelial cells derived from different tissue compartments. **Figure S3.** Correlation between the HM450 and Sequenom EpiTYPER. Infinium HumanMethylation450 methylation accurately reflects DNA methylation levels in HPAEC and HPVEC. **Figure S4.** Coordinated gene expression and DNA methylation in "Cardiovascular System Development and Function, Connective Tissue Development and Function, Skeletal and Muscular System Development and Function" pathway genes in HPAEC and HPVEC. **Figure S5.** Scatterplot showing relationship between DNA methylation and gene expression in venous and arterial cells. **Figure S6.** Proportion of probes associated with specific gene expression change by genomic location. **Figure S7.** NOS3 Sequenom Assays used to measure regional methylation in HPVEC and HPAEC for Assay 1 (A), and Assay 2 (B).
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###### Additional file 2: Table S2

All probes showing higher average β values by 10% or more in HPVEC than HPAEC.
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###### Additional file 3: Table S3

All probes showing higher average β values by 10% or more in HPAEC HPVEC.
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###### Additional file 4: Table S1

DNMT-associated DNA methylation values in HPAEC and HPVEC cells.
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###### Additional file 5: Table S4

IPA (Ingenuity Pathway Analysis) in differentially methylated probes by 10% (DNA methylation) and differentially expressed by 0.5 Log FC (located near transcription start sites). **Table S5.** Gene Ontology analysis in differentially methylated probes by 10% (DNA methylation) and differentially expressed by 0.5 Log FC (located near transcription start sites). **Table S6.** List of probes showing coordinated methylation (less methylated) and gene expression (higher expression) in HPAEC. **Table S7.** List of probes showing coordinated methylation (less methylated) and gene expression (higher expression) in HPVEC. **Table S8.** List of selected probes associated in genes shown in Table [1](#T1){ref-type="table"}. **Table S9.** List of probes on selected miRs.
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